New strategies for chemokine inhibition and modulation. You take the high road and I'll take the low road

Biochemical Pharmacology

Volumn 54, Issue 12, 1997, Pages 1271-1280

  McFadden, Grant ^a,b   Kelvin, David ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Chemotactic cytokines; Drug therapies; Inflammation; Viral inhibitors

Indexed keywords

ANTIBODY; ANTIINFLAMMATORY AGENT; CHEMOKINE; INTERLEUKIN 8; LYMPHOTACTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; RANTES; THROMBOCYTE FACTOR 4;

AMINO ACID COMPOSITION; BINDING AFFINITY; BINDING SITE; CELL SURFACE; CHRONIC INFLAMMATION; DRUG DESIGN; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; MUTATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW;

EID: 0030725180     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00182-2     Document Type: Article

References (94)

1. Oppenheim JJ, Zacharier MN, Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol. 9:1991;617-648.
2. Bacon KB, Schall TJ. Chemokines as mediators of allergic inflammation. Int Arch Allergy Immunol. 109:1996;97-109.
3. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol. 55:1994;97-179.
4. Kunkel SL, Lukacs N, Strieter RM. Chemokines and their role in human disease. Agents Actions Suppl. 46:1995;11-22.
5. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration The multistep paradigm . Cell. 76:1994;301-314.
6. Wells TNC, Power CA, Lusti-Narasimhan M, Hoogewerf AJ, Cooke RM, Chung C, Peitsch MC, Proudfoot AEI. Selectivity and antagonism of chemokine receptors. J Leukoc Biol. 59:1996;53-60.
7. Clark-Lewis I, Kim K-S, Rajarathnam K, Gong J-H, Dewald B, Moser B, Baggiolini M, Sykes BD. Structure-activity relationships of chemokines. J Leukoc Biol. 57:1995;703-711.
8. Horuk R, Peiper SC. Chemokines - Molecular double agents. Curr Biol. 6:1996;1581-1582.
9. Broxmeyer HE, Cooper S, Hague N, Benninger L, Sarris A, Cornetta K, Vadhan-Raj S, Hendrie P, Mantel C. Human chemokines Enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice . Ann Hematol. 71:1995;235-246.
10. Broxmeyer HE, Sherry B, Cooper S, Lu L, Maze R, Beckmann MP, Cerami A, Ralph P. Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression. J Immunol. 150:1993;3448-3458.
11. Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, Honjo T. Signal sequence trap A cloning strategy for secreted proteins and type I membrane proteins . Science. 261:1993;600-603.
12. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T. Defects in B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 382:1996;635-638.
13. Strieter RM, Polverini RJ, Arenberg DA, Kunkel SL. The role of CXC chemokines as regulators of angiogenesis. Shock. 4:1995;155-160.
14. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med. 182:1995;155-162.
15. Strieter RM, Kunkel SL, Arenberg DA, Burdick MD, Polverini PJ. Interferon-γ-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun. 210:1995;51-57.
16. Clore GM, Gronenborn AM. Three-dimensional structures of α and β chemokines. FASEB J. 9:1995;57-62.
17. Baldwin ET, Weber IT, St. Charles R, Xuan JC, Appella E, Yamada M, Matsushima K, Edwards BFP, Clore GM, Wlodawer A. Crystal structure of interleukin 8 Symbiosis of NMR and crystallography . Proc Natl Acad Sci USA. 88:1991;502-506.
18. Zhang X, Chen L, Bancroft DP, Lai CK, Maione TE. Crystal structure of recombinant platelet factor 4. Biochemistry. 33:1994;8361-8366.
19. Chung C, Cooke RM, Proudfoot AEI, Wells TNC. The three-dimensional solution structure of RANTES. Biochemistry. 34:1995;9307-9314.
20. 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochemistry. 35:1996;6569-6584.
21. Skelton NJ, Aspiras F, Ogez J, Schall TJ. Proton NMR assignments and solution conformation of RANTES, a chemokine of the C-C type. Biochemistry. 34:1995;5329-5342.
22. Kelvin DJ, Michiel DF, Johnston JA, Lloyd AR, Sprenger H, Oppenheim JJ, Wang J-M. Chemokines and serpentines The molecular biology of chemokine receptors . J Leukoc Biol. 54:1993;604-612.
23. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol. 12:1994;593-633.
24. Raport CJ, Schweickart VL, Chantry D, Eddy RL, Shows TB, Godiska R, Gray PW. New members of the chemokine receptor gene family. J Leukoc Biol. 59:1996;18-23.
25. Premack BA, Schall TJ. Chemokine receptors Gateways to inflammation and infection . Nature Med. 2:1996;1174-1178.
26. Witt DP, Lander AD. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol. 4:1994;394-400.
27. Rot A. Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro neutrophil migration by haptotactic mechanism. Eur J Immunol. 23:1993;303-306.
28. Webb LMC, Ehrengruber MU, Clark-Lewis I, Baggiolini M, Rot A. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci USA. 90:1993;7158-7162.
29. Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y, Matsushima K. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature. 365:1993;654-657.
30. Larsen CG, Thomsen MK, Gesser B, Thomsen PD, Deleuran BW, Nowak J, Skodt V, Thomsen HK, Deleuran M, Thestrup-Perdersen K, Harada A, Matsushima K, Menne T. The delayed-type hypersensitivity reaction is dependent on IL-8 Inhibition of a tuberculin skin reaction by an anti-IL-8 monoclonal antibody . J Immunol. 155:1995;2151-2157.
31. Wada T, Tomosugi N, Naito T, Yokoyama H, Kobayashi K, Harada A, Mukaida N, Matsushima K. Prevention of proteinuria by the administration of anti-interleukin 8 antibody in experimental acute immune complex-induced glomerulonephritis. J Exp Med. 180:1994;1135-1140.
32. Harada A, Sekido N, Kuno K, Akiyama M, Kasahara T, Nakanishi I, Mukaida N, Matsushima K. Expression of recombinant rabbit IL-8 in Escherichia coli and establishment of the essential involvement of IL-8 in recruiting neutrophils into lipopolysaccharide-induced inflammatory site of rabbit skin. Int Immunol. 5:1993;681-690.
33. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol. 56:1994;559-564.
34. Wada T, Yokoyama H, Furuichi K, Kobayashi K, Harada K, Naruto M, Su S, Akiyama M, Mukaida N, Matsushima K. Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). FASEB J. 10:1996;1418-1425.
35. Hebert CA, Vitangcol RV, Baker JB. Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J Biol Chem. 266:1991;18989-18994.
36. 2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. J Biol Chem. 266:1991;23128-23134.
37. Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci USA. 90:1993;3574-3577.
38. Williams G, Borkakoti N, Bottomley GA, Cowan I, Fallowfield AG, Jones PS, Kirtland SJ, Price GJ, Price L. Mutagenesis studies of interleukin-8. J Biol Chem. 271:1996;9579-9586.
39. Hammond ME, Shyamala V, Siani MA, Gallegos CA, Feucht PH, Abbott J, Lapointe GR, Moghadam M, Khoja H, Zakel J, Tekamp-Olson P. Receptor recognition and specificity of interleukin-8 is determined by residues that cluster near a surface-accessible hydrophobic pocket. J Biol Chem. 271:1996;8228-8235.
40. Moser B, Dewald B, Barrella L, Schumacher C, Baggiolini M, Clark-Lewis I. Interleukin-8 antagonists generated by N-terminal modification. J Biol Chem. 268:1993;7125-7128.
41. Zhang YJ, Rutledge BJ, Rollins BJ. Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. J Biol Chem. 269:1994;15918-15924.
42. Zhang Y, Rollins BJ. A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol Cell Biol. 15:1995;4851-4855.
43. 2-terminal residues. J Exp Med. 181:1995;631-640.
44. Proudfoot AEI, Power CA, Hoogewerf AJ, Montjovent M-O, Borlat F, Offord RE, Wells TNC. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem. 271:1996;2599-2603.
45. Bates P. Chemokine receptors and HIV-1 An attractive pair? Cell. 86:1996;1-3.
46. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Mazio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381:1996;661-666.
47. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RJ, Doms RW. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion co-factors. Cell. 85:1996;1149-1158.
48. + cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381:1996;667-673.
49. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC CKR5 A RANTES MIP-1α, M1P-1β, receptor as a fusion cofactor for macrophage-tropic HIV-1 . Science. 272:1996;1955-1958.
50. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor . Science. 272:1996;872-877.
51. Arenzana-Seisdedos F, Virelizier J-L, Rousset D, Clark-Lewis I. HIV blocked by chemokine antagonist. Nature. 383:1996;400.
52. Hayashi S, Kurdowska A, Miller EJ, Albright ME, Girten BE, Cohen AB. Synthetic hexa- and heptapeptides that inhibit IL-8 from binding to and activating human blood neutrophils. J Immunol. 154:1995;814-824.
53. Harada A, Mukaida N, Matsushima K. Interleukin 8 as a novel target for intervention therapy in acute inflammatory diseases. Mol Med Today. 11:1996;482-489.
54. Howard O, Ben-Baruch A, Oppenheim JJ. Chemokines Toward identifying molecular targets for therapeutic agents . Trends Biotechnol. 14:1996;46-51.
55. Tanaka Y, Adams DH, Shaw S. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol Today. 14:1993;111-115.
56. Tanaka Y, Adams DH, Shaw S. Regulation of leukocyte recruitment by proadhesive cytokines immobilized on endothelial proteoglycan. Curr Top Microbiol Immunol. 184:1993;99-106.
57. Lider O, Hershkoviz R, Kachalsky SG. Interactions of migrating T lymphocytes, inflammatory mediators, and the extracellular matrix. Crit Rev Immunol. 15:1995;271-283.
58. Nietfeld JJ. Cytokines and proteoglycans. Experientia. 49:1993;456-469.
59. Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1β Nature. 361:1993;79-82.
60. + T lymphocytes to intact or heparinase-treated subendothelial extracellular matrix by diffusible or anchored RANTES and MIP-1β J Immunol. 153:1994;4899-4906.
61. Roberts R, Gallagher J, Spooncer E, Allen TD, Bloomfield F, Dexter TM. Heparan sulphate bound growth factors A mechanism for stromal cell mediated haemopoiesis . Nature. 332:1988;376-378.
62. Gilat D, Cahalon L, Hershkoviz R, Lider O. Interplay of T cells and cytokines in the context of enzymatically modified extracellular matrix. Immunol Today. 17:1996;16-20.
63. Clarke D, Katoh O, Gibbs RV, Griffiths SD, Gordon MY. Interaction of interleukin 7 (IL-7) with glycosaminoglycans and its biological relevance. Cytokine. 7:1995;325-330.
64. Miao H-Q, Ishai-Michaeli R, Atzmon R, Peretz T, Vlodavsky I. Sulfate moieties in the subendothelial extracellular matrix are involved in basic fibroblast growth factor sequestration, dimerization, and stimulation of cell proliferation. J Biol Chem. 271:1996;4879-4886.
65. Vlodavsky I, Miao H-Q, Medalion B, Danagher P, Ron D. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev. 15:1996;177-186.
66. Slavin J. Fibroblast growth factors At the heart of angiogenesis . Cell Biol Int. 19:1995;431-444.
67. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. Heparin structure interactions with basic fibroblast growth factor. Science. 271:1996;1116-1120.
68. Venkataraman G, Sasisekharan V, Herr AB, Ornitz DM, Waksman G, Cooney CL, Langer R, Sasisekharan R. Preferential self-association of basic fibroblast growth factor is stabilized by heparin during receptor dimerization and activation. Proc Natl Acad Sci USA. 93:1996;845-850.
69. Green PJ, Walsh FS, Doherty P. Promiscuity of fibroblast growth factor receptors. Bioessays. 18:1996;639-646.
70. Wellstein A, Czubayko F. Inhibition of fibroblast growth factors. Breast Cancer Res Treat. 38:1996;109-119.
71. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem. 268:1993;23906-23914.
72. Reich-Slotky R, Bonneh-Barkay D, Shaoul E, Bluma B, Svahn CM, Ron D. Differential effect of cell-associated heparan sulfates on the binding of keratinocyte growth factor (KGF) and acidic fibroblast growth factor to the KGF receptor. J Biol Chem. 269:1994;32279-32285.
73. Wu D, Kan M, Sato GH, Okamoto T, Sato JD. Characterization and molecular cloning of putative binding protein for heparin-binding growth factors. J Biol Chem. 266:1991;16778-16785.
74. Czubayko F, Smith RV, Chung HC, Wellstein A. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J Biol Chem. 269:1994;28243-28248.
75. Liaudet-Coopman ED, Wellstein A. Regulation of gene expression of a binding protein for fibroblast growth factors by retinoic acid. J Biol Chem. 271:1996;21303-21308.
76. Okamoto T, Tanaka Y, Kan M, Sakamoto A, Takada K, Sato JD. Expression of fibroblast growth factor binding protein HBp17 in normal and tumor cells. In Vitro Cell Dev Biol Animal. 32:1996;69-71.
77. Smith GL. Virus proteins that bind cytokines, chemokines or interferons. Curr Opin Immunol. 8:1996;467-471.
78. Senkevich TG, Bugert JJ, Sisler JR, Koonin EV, Darai G, Moss B. Genome sequence of a human tumorigenic poxvirus - Prediction of specific host response-evasion genes. Science. 273:1996;813-816.
79. MacDonald MR, Li X-Y, Virgin HW. Late expression of a β chemokine homolog by murine cytomegalovirus. J Virol. 71:1997;1671-1678.
80. Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science. 274:1996;1739-1744.
81. Murphy PM. Molecular piracy of chemokine receptors by herpesviruses. Infect Agents Dis. 3:1994;137-154.
82. Barry M and McFadden G, Virus-encoded cytokines and cytokine receptors. Parasitology (Suppl), in press.
83. Upton C, Mossman K, McFadden G. Encoding of a homolog of the IFN-γ receptor by myxoma virus. Science. 258:1992;1369-1372.
84. Mossman K, Upton C, McFadden G. The myxoma virus-soluble interferon-γ receptor homolog, M-T7, inhibits interferon-γ in a species-specific manner. J Biol Chem. 270:1995;3031-3038.
85. Mossman K, Nation P, Macen J, Garbutt M, Lucas A, McFadden G. Myxoma virus M-T7, a secreted homolog of the interferon-γ receptor, is a critical virulence factor for the development of myxomatosis in European rabbits. Virology. 215:1996;17-30.
86. Lalani AS, Graham K, Mossman K, Rajarathnam K, Clark-Lewis I, Kelvin D and McFadden G, The purified myxoma virus IFN-γ receptor homolog, M-T7, interacts with the heparin binding domains of chemokines. J Virol, in press.
87. Graham KA, Lalani AS, Macen JL, Ness TL, Barry M, Liu L-Y, Lucas A, Clark-Lewis I, Moyer RW, McFadden G. The T1/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues. Virology. 229:1997;12-24.
88. Patel AH, Gaffney DF, Subak-Sharpe JH, Stow ND. DNA sequence of the gene encoding a major secreted protein of vaccinia virus, strain Lister. J Gen Virol. 71:1990;2013-2021.
89. Martinez-Pomares L, Thompson JP, Moyer RW. Mapping and investigation of the role in pathogenesis of the major unique secreted 35-kDa protein of rabbitpox virus. Virology. 206:1995;591-600.
90. Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol. 313:1992;355-364.
91. Waltenberger J, Mayr U, Frank H, Hombach V. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol. 28:1996;1523-1529.
92. Luster AD, Greenberg SM, Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med. 182:1995;219-231.
93. Gupta SK, Hassel T, Singh JP. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA. 92:1995;7799-7803.
94. Graham GJ, Wilkinson PC, Nibbs RJB, Lowe S, Kolset SO, Parker A, Freshney MG, Tsang ML-S, Pragnell IB. Uncoupling of stem cell inhibition from monocyte chemoattraction in MIP-1α by mutagenesis of the proteoglycan binding site. EMBO J. 15:1996;6506-6515.